Orris

Mechanism of action of tricyclic antidepressants

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Searching PubMed

tricyclic antidepressants mechanism of action

I have enough material from the textbooks to give a thorough answer. Here's the mechanism of action of tricyclic antidepressants (TCAs):

Mechanism of Action of Tricyclic Antidepressants (TCAs)

1. Primary action: monoamine reuptake inhibition

The core pharmacological action of TCAs is blockade of the presynaptic norepinephrine transporter (NET) and serotonin transporter (SERT), preventing reuptake of norepinephrine (NE) and serotonin (5-HT) into the presynaptic nerve terminal. This increases the concentration of these neurotransmitters in the synaptic cleft, prolonging their action at postsynaptic receptors - the classic "monoamine hypothesis" of depression treatment (Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 1708; Guyton and Hall Textbook of Medical Physiology, p. 2528).
  • Secondary amine TCAs (desipramine, nortriptyline, protriptyline) are relatively selective NET inhibitors.
  • Tertiary amine TCAs (imipramine, amitriptyline, clomipramine) inhibit both SERT and NET, with tertiary amines generally having greater affinity for the serotonin transporter (Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 1322).
By blocking reuptake, TCAs increase synaptic availability of NE and 5-HT "so that these transmitters have a prolonged action on the postsynaptic receptors" (Guyton and Hall, p. 2528).

2. Downstream/adaptive changes

The antidepressant effect is delayed by 2-4 weeks despite immediate reuptake blockade, which is classically attributed to slower, adaptive changes in receptor sensitivity - most notably downregulation and desensitization of postsynaptic beta-adrenergic and serotonin receptors, and alterations in intracellular signaling (cAMP, CREB, BDNF) with chronic dosing, rather than the acute reuptake blockade itself.

3. Additional receptor actions (responsible for side effects, and possibly contribute to efficacy)

TCAs are not selective - they also block:
  • H1 histamine receptors -> sedation, weight gain
  • α1-adrenergic receptors -> orthostatic hypotension
  • Muscarinic (cholinergic) receptors -> dry mouth, blurred vision, constipation, urinary retention, tachycardia
  • 5-HT2A receptors
  • Voltage-gated sodium channels (cardiac/neuronal) -> responsible for cardiac conduction toxicity (widened QRS) and antiarrhythmic-like membrane-stabilizing effects, which is why TCA overdose causes life-threatening cardiotoxicity and seizures
(Stahl's Essential Psychopharmacology; Goodman & Gilman's, p. 1708-1709)
One TCA, amoxapine, additionally acts as a dopamine receptor antagonist, giving it a distinct risk of extrapyramidal side effects such as tardive dyskinesia.

Clinical correlation

This combined receptor profile explains both the therapeutic uses (depression, chronic pain/neuropathic pain via NE/5-HT effects on nociception, insomnia at low doses via H1 blockade) and the prominent side-effect burden (anticholinergic effects, orthostatic hypotension, sedation, cardiotoxicity in overdose) that has made TCAs largely second-line compared to SSRIs/SNRIs.
Evidence note: A 2024 systematic review/meta-analysis in BMJ Mental Health (Kamp et al., PMID 39093721) re-examined the benefit-harm balance of TCAs in major depressive disorder, and a related 2024 Maturitas meta-analysis (PMID 39089048) specifically addressed TCA-associated fall and fracture risk in older adults - both relevant to the anticholinergic/antihistaminergic and cardiac sodium-channel effects described above, but neither contradicts the established mechanism of action.

Short

TCA mechanism, short version:
  • Block reuptake of norepinephrine (NET) and serotonin (SERT) at the presynaptic terminal, increasing their synaptic levels.
  • Secondary amines (nortriptyline, desipramine) → mostly NE-selective; tertiary amines (amitriptyline, imipramine, clomipramine) → block both NE and 5-HT.
  • Chronic use leads to downregulation/desensitization of postsynaptic beta-adrenergic and serotonin receptors, which correlates with the delayed (2-4 week) clinical onset.
  • Also block H1 (sedation), α1-adrenergic (hypotension), muscarinic (anticholinergic effects), and cardiac sodium channels (cardiotoxicity in overdose) - these off-target actions drive most side effects.
This is a shared conversation. Sign in to Orris to start your own chat.